Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
12:41pm, Wednesday, 05'th Nov 2025
AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.
Amgen: Q3 Earnings Indicate Strong Emphasis On R&D
12:40pm, Wednesday, 05'th Nov 2025
Amgen remains a compelling long-term buy, supported by robust R&D investment and a promising drug pipeline for future growth. AMGN delivered strong Q3 results, with double-digit revenue and volume gro
Amgen Inc (AMGN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments Propel Future Prospects
12:01am, Wednesday, 05'th Nov 2025
Revenue: Increased 12% year over year to $9.6 billion.Volume Growth: Up 14% year over year.Non-GAAP Operating Margin: 47%.Non-GAAP R&D Growth: 31% year over ye
Amgen (AMGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
09:01pm, Tuesday, 04'th Nov 2025
Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Stree
Amgen Inc. (AMGN) Q3 2025 Earnings Call Transcript
07:36pm, Tuesday, 04'th Nov 2025
Amgen Inc. ( AMGN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Casey Capparelli Robert Bradway - Chairman, CEO & President Peter Griffith - Executive VP & CFO Murdo Gordon
Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates
06:16pm, Tuesday, 04'th Nov 2025
Amgen (AMGN) came out with quarterly earnings of $5.64 per share, beating the Zacks Consensus Estimate of $5 per share. This compares to earnings of $5.58 per share a year ago.
Amgen Raises Full-Year Outlook After Third-Quarter Profit, Sales Jump
04:33pm, Tuesday, 04'th Nov 2025
The biotechnology company reported a profit of $3.22 billion thanks to a 12% rise in product sales.
Amgen Inc (AMGN) Q3 2025 Earnings: GAAP EPS Surges to $5.93, Revenue Hits $9.6 Billion, Exceeding Estimates
04:31pm, Tuesday, 04'th Nov 2025
Revenue: Achieved $9.6 billion, surpassing the estimated $8.97 billion, marking a 12% increase year-over-year.GAAP EPS: Increased 14% to $5.93, exceeding the q
Amgen profit beats estimates, weight-loss data due by year-end
04:04pm, Tuesday, 04'th Nov 2025
Amgen on Tuesday reported quarterly financial results that beat Wall Street expectations as product sales rose 12%, offsetting higher operating expenses related to experimental weight-loss drug MariTi
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
04:01pm, Tuesday, 04'th Nov 2025
THOUSAND OAKS, Calif. , Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025.
Wall Street Week Ahead
07:07am, Sunday, 02'nd Nov 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
04:01pm, Friday, 31'st Oct 2025
THOUSAND OAKS, Calif. , Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the fourth quarter of 2025.
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
12:20pm, Friday, 31'st Oct 2025
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
10:00am, Friday, 31'st Oct 2025
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
09:00am, Friday, 31'st Oct 2025
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE Tria
